Cellarity is a biotech company focused on designing medicines against the cell as opposed to a single molecular target by leveraging a unique combination of expertise across system and network biology, high-resolution data, and machine learning to unlock treatments in a large number of therapeutic areas.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
10/04/2022 | Series C | $121MM | $xx.xx | $618.28MM | Flagship Pioneering, Hanwha Impact Partners, Kyowa Kirin | |
Price per Share
$xx.xx
Shares Outstanding
16,462,585
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Flagship Pioneering, Hanwha Impact Partners, Kyowa Kirin
|
||||||
02/25/2021 | Series B | $125.9MM | $xx.xx | $398.45MM | Bankque Pictet, Blackrock, Flagship Pioneering, The Baupost Group | |
Price per Share
$xx.xx
Shares Outstanding
20,983,333
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bankque Pictet, Blackrock, Flagship Pioneering, The Baupost Group
|
||||||
12/10/2019 | Series A | $11.4MM | $xx.xx | $82.99MM | Flagship Pioneering | |
Price per Share
$xx.xx
Shares Outstanding
11,399,900
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Flagship Pioneering
|
||||||
12/10/2019 | Series A-1 | $18.7MM | $xx.xx | $82.99MM | Flagship Pioneering | |
Price per Share
$xx.xx
Shares Outstanding
9,348,822
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Flagship Pioneering
|